Order before 3pm, dispatched same day
Order before 3pm, dispatched same day Research Use Only
Pay by Card / Apple Pay
99% Purity Money Back Guarantee Retatrutide Now Available

What Is Retatrutide? Triple Agonist GLP-1 Compound Explained

Back to library
peptide

What Is Retatrutide? Triple Agonist GLP-1 Compound Explained

13 min read

Last Updated: April 2026

Retatrutide (LY3437943) is an investigational injectable compound developed by Eli Lilly that simultaneously activates three hormone receptors: GLP-1, GIP, and glucagon. Semaglutide activates one receptor. Tirzepatide activates two. Retatrutide activates all three. In Phase 2 clinical trials published in the New England Journal of Medicine, it produced 24.2% mean body weight reduction at 48 weeks – the largest result recorded for an anti-obesity compound at that time. Phase 3 TRIUMPH-4 data reported in December 2025 extended that to 28.7% at 68 weeks.

It has not received approval from the MHRA, FDA, or EMA. It is not available on prescription in the UK. Research-grade retatrutide is available separately as a laboratory compound for in vitro research use. This guide covers what retatrutide is, how its mechanism differs from semaglutide and tirzepatide, what the clinical trial data shows, and where the regulatory timeline stands as of April 2026.

Key Takeaways

  • Retatrutide is a triple agonist: GLP-1 + GIP + glucagon receptors – the first compound in this class to reach Phase 3 clinical trials
  • Phase 2 (NEJM, 2023): Up to 24.2% mean body weight reduction at 48 weeks on the 12 mg dose – larger than semaglutide (~15%) or tirzepatide (~22.5%) in their respective trials
  • Phase 3 TRIUMPH-4 (December 2025): 28.7% mean body weight reduction at 68 weeks on 12 mg – the largest result recorded in any obesity pharmacotherapy trial to date
  • The glucagon receptor component is what separates retatrutide from all approved alternatives – it increases energy expenditure and promotes hepatic fat oxidation, mechanisms not present in semaglutide or tirzepatide
  • New safety signal in TRIUMPH-4: dysesthesia (abnormal skin sensation) in 8.8% at 9 mg and 20.9% at 12 mg vs 0.7% on placebo – not seen with semaglutide or tirzepatide
  • UK regulatory status: Not MHRA approved. Not available on NHS or private prescription. Realistic availability on prescription: 2028 at the earliest

The GLP-1 Landscape That Retatrutide Steps Into

To understand where retatrutide fits, it helps to understand the progression that got here. In 2021, Wegovy (semaglutide) arrived – once-weekly injection, GLP-1 receptor agonist only, approximately 15% mean weight loss at 68 weeks in the STEP 1 trial. In 2022, Mounjaro (tirzepatide) arrived – dual GLP-1/GIP agonist, approximately 22.5% mean weight loss in SURMOUNT-1. The addition of GIP agonism produced a meaningful step up.

Retatrutide adds a third hormone system entirely – glucagon receptor agonism. The numbers keep stepping up. The mechanism explains why.

Alex had been on semaglutide for 14 months – lost 11% of his bodyweight, then stalled. His clinic offered tirzepatide as the next step. He wanted to understand what was actually different about the mechanism before switching. He found the NEJM Phase 2 retatrutide paper and read it cover to cover. Not because he could access retatrutide on prescription – he couldn’t – but because understanding the progression from single to dual to triple receptor agonism helped him understand what each compound was actually doing metabolically. That kind of mechanistic literacy changes how you evaluate any treatment decision.

Research-Grade Retatrutide in Stock

Available for in vitro laboratory research use. Batch-specific COA, HPLC purity verification, mass spectrometry identity confirmation.

Browse Retatrutide →

Mechanism of Action: Three Receptor Pathways in One Molecule

Retatrutide’s defining feature is that it activates all three hormone receptor systems simultaneously. Each contributes differently to the metabolic outcomes observed in trials.

GLP-1 Receptor Agonism

GLP-1 (glucagon-like peptide-1) is an incretin hormone secreted from intestinal L-cells after meals. GLP-1 receptor activation does four things: stimulates glucose-dependent insulin secretion from pancreatic beta cells; suppresses glucagon release; slows gastric emptying, prolonging the sensation of fullness; and acts centrally on the hypothalamus and brainstem to reduce appetite. This combination of peripheral metabolic effects and central appetite suppression is the foundation of all current obesity medicines.

In retatrutide, the GLP-1 component provides the appetite suppression and insulin-sensitising effects. The compound shows somewhat lower GLP-1 potency than semaglutide alone – a deliberate design choice that balanced efficacy across three pathways rather than maximising one.

GIP Receptor Agonism

GIP (glucose-dependent insulinotropic polypeptide) enhances insulin secretion from pancreatic beta cells in a glucose-dependent manner. It also influences fat metabolism and energy storage in adipose tissue – improving insulin sensitivity in ways not achievable through GLP-1 agonism alone. Research published in Cell Metabolism (Coskun et al., 2022) demonstrated that GIP agonism adds meaningful metabolic benefit beyond GLP-1 activity, particularly in lipid metabolism.

Retatrutide demonstrates higher GIP receptor potency than either semaglutide (zero GIP activity) or tirzepatide. This enhanced GIP component is one proposed explanation for why retatrutide’s weight loss results exceed tirzepatide’s despite both being once-weekly injectable treatments.

Glucagon Receptor Agonism: The Key Differentiator

This is the pathway that separates retatrutide from everything that came before it. No currently approved obesity medicine activates the glucagon receptor.

When glucagon receptor agonism is combined with GLP-1 agonism, the insulin-stimulating effects of GLP-1 counterbalance the glucose-raising effects of glucagon. The net glycaemic result is neutral or positive. The other effects of glucagon receptor activation remain – and they are metabolically significant:

  • Increased energy expenditure: Glucagon promotes thermogenesis in brown adipose tissue and increases basal metabolic rate – which means the body burns more calories at rest, an effect that neither GLP-1 nor GIP agonism provides
  • Hepatic fat oxidation: Glucagon stimulates the liver to oxidise stored fat. In Phase 2 trials, retatrutide reduced liver fat by up to 82-86% at 48 weeks – substantially exceeding what semaglutide alone achieves
  • Lipolysis in adipose tissue: Glucagon reduces lipogenesis and induces lipolysis, increasing the release of fatty acids for energy use
  • LDL cholesterol reduction: Phase 2 data showed approximately 20% reductions in LDL cholesterol, possibly linked to glucagon’s effect on PCSK9 degradation in hepatocytes

Retatrutide vs Semaglutide vs Tirzepatide

Note: No head-to-head trial has been published. Comparisons below are drawn from separate trials with different populations, study durations, and endpoints.

Semaglutide (Wegovy) Tirzepatide (Mounjaro) Retatrutide
Receptors targeted GLP-1 only GLP-1 + GIP GLP-1 + GIP + glucagon
UK approval status MHRA approved MHRA approved Not approved – Phase 3 trials ongoing
Phase 2 weight loss ~15% at 68 weeks (STEP 1) ~22.5% at 72 weeks (SURMOUNT-1) 24.2% at 48 weeks (NEJM, 2023)
Phase 3 weight loss ~20.7% at 72 weeks ~22.5% at 72 weeks 28.7% at 68 weeks (TRIUMPH-4, Dec 2025)
Liver fat reduction Moderate (via weight loss) Greater than semaglutide Up to 82-86% (Phase 2a, Nature Medicine 2024)
Energy expenditure Modest increase Moderate increase Greater increase (glucagon-driven thermogenesis)
New safety signal Rare thyroid C-cell tumours (rodent data) Rare thyroid C-cell tumours (class effect) Dysesthesia (8.8-20.9% at higher doses)

Phase 2 Clinical Trial Data

NEJM Phase 2 – Obesity (Jastreboff et al., 2023)

Randomised, double-blind, placebo-controlled. 338 adults with obesity or overweight with at least one comorbidity. 48-week duration, multiple dose cohorts.

  • 12 mg weekly dose: 24.2% mean body weight reduction vs 2.1% with placebo
  • 8 mg weekly dose: 17.5% mean body weight reduction
  • 4 mg weekly dose: 8.7% – confirming dose-dependent response
  • 72% of participants with prediabetes at baseline reverted to normoglycemia
  • Significant improvements in waist circumference, blood pressure, fasting glucose, insulin, LDL cholesterol, and HbA1c
  • GI side effects were the most common adverse events – nausea, vomiting, diarrhoea – consistent with GLP-1-containing therapies, primarily during dose escalation

Lancet Phase 2 – Type 2 Diabetes (Rosenstock et al., 2023)

  • 16.9% mean body weight reduction at 36 weeks on the highest dose
  • HbA1c improved by 2.2% on the highest dose
  • 77-82% of participants achieved normoglycaemia (HbA1c ≤6.5%) at 36 weeks
  • Superior glycaemic and weight outcomes vs dulaglutide 1.5 mg (an established GLP-1 RA with proven cardiovascular benefits), used as active comparator

Nature Medicine Phase 2a – Liver Disease (MASH)

  • 12 mg dose: up to 82% reduction in liver fat at 24 weeks
  • 93% of participants on 12 mg achieved normal liver fat levels
  • Significant reductions in liver enzymes (ALT, AST) indicating reduced hepatic inflammation
  • These liver outcomes substantially exceed what is achievable with semaglutide alone

The liver findings matter because MASH currently has no approved pharmacological treatments in the UK or US. Retatrutide’s glucagon receptor component – driving hepatic fat oxidation – is the likely mechanism behind these superior liver outcomes.

Lab-Grade Retatrutide with Full COA Documentation

For in vitro research use. Every batch independently verified. No guessing what’s in the vial.

Shop the Full Range →

Phase 3: The TRIUMPH Programme

Following Phase 2, Eli Lilly launched the TRIUMPH (TRIple hormone receptor agonist for the Management of Patients affected by cHronic weight complications) Phase 3 programme in late 2023. Eight trials across multiple indications, with primary endpoint data expected throughout 2026.

Trial Indication Status (April 2026)
TRIUMPH-1 Obesity (BMI ≥30 or ≥27 with comorbidity) Ongoing – results expected 2026
TRIUMPH-2 Obesity – vs placebo and active control Ongoing – results expected 2026
TRIUMPH-3 Type 2 diabetes head-to-head vs dulaglutide Ongoing
TRIUMPH-4 Obesity + knee osteoarthritis COMPLETED Dec 2025: 28.7% weight loss at 68 weeks
TRIUMPH-5 Cardiovascular outcomes Ongoing – long-term trial
REDEFINE MASLD (liver disease) Ongoing
Additional trials Sleep apnoea, chronic low back pain Ongoing

TRIUMPH-4: The First Phase 3 Result (December 2025)

TRIUMPH-4 enrolled 445 adults with obesity or overweight and knee osteoarthritis, without diabetes. Duration: 68 weeks.

  • 12 mg dose: 28.7% mean body weight reduction (placebo-adjusted: 26.6%) – the largest result recorded in any obesity pharmacotherapy trial to date
  • Average absolute weight loss: approximately 32.3 kg (71.2 lbs) in the highest dose group
  • Significant reductions in knee pain: more than 1 in 8 participants became completely free of knee pain by trial end
  • Meaningful improvements in non-HDL cholesterol, high-sensitivity CRP, triglycerides, and systolic blood pressure (reduced by 14.0 mmHg)
  • New safety signal: dysesthesia (abnormal skin sensation/tingling) in 8.8% at 9 mg and 20.9% at 12 mg vs 0.7% on placebo – not previously observed with semaglutide or tirzepatide

The dysesthesia signal requires investigation. Its mechanism is not established, and further characterisation across the remaining TRIUMPH trials will be essential before regulators can assess its significance. It is a genuine safety question that did not exist for semaglutide or tirzepatide at approval.

David, a sports medicine researcher in Edinburgh, had been watching the TRIUMPH programme since the Phase 2 NEJM paper. When TRIUMPH-4 reported in December 2025 – 28.7% at 68 weeks, the knee pain data, and the new dysesthesia signal all at once – his first reaction was that the dysesthesia finding was the most important result in the whole data package. Not because it invalidated the compound, but because it was a genuine unknown. He wanted to understand the mechanism before forming a view. That’s the right response to new safety data.

What Research Is Examining Beyond Weight Loss

Liver Disease (MASH/MASLD)

MASH is a progressive liver condition occurring in a substantial proportion of people with obesity and type 2 diabetes. It can advance to cirrhosis and liver failure. No pharmacological treatment is currently approved for MASH in the UK. The Phase 2a Nature Medicine data showing up to 82% liver fat reduction positions retatrutide as potentially the most effective pharmacological intervention in this space. The REDEFINE trial is examining this as a dedicated Phase 3 endpoint.

Osteoarthritis

TRIUMPH-4’s knee pain reduction findings are notable. The timeline of pain reduction in the trial is faster than would be expected from weight loss effects alone, suggesting potential direct anti-inflammatory effects. Whether this reflects GLP-1’s known anti-inflammatory properties, glucagon’s effects, or both, is an active research question.

Cardiovascular Outcomes

Semaglutide’s SELECT trial (2023) demonstrated a 20% reduction in major adverse cardiovascular events in people with cardiovascular disease. TRIUMPH-5 is examining whether retatrutide achieves comparable cardiovascular risk reduction. Early biomarker data from TRIUMPH-4 – reductions in non-HDL cholesterol, CRP, triglycerides, and blood pressure – is consistent with the pattern seen before SELECT confirmed cardiovascular benefit for semaglutide.

UK Regulatory Status and Timeline

Current status (April 2026): Retatrutide has not received MHRA, FDA, or EMA marketing authorisation. It cannot be legally prescribed or dispensed in the UK. It is accessible only within authorised clinical trials.

The estimated regulatory timeline:

  • 2026: Remaining TRIUMPH trial primary endpoint data expected (TRIUMPH-1, 2, 3, 5, REDEFINE)
  • Late 2026 to Q1 2027: Potential FDA New Drug Application submission by Eli Lilly, if Phase 3 data is satisfactory
  • 2027-2028: Possible FDA approval (priority review could accelerate to mid-2027; standard review would push to 2028)
  • MHRA approval typically follows FDA by 6-12 months – though the MHRA approved a higher semaglutide dose before the FDA in early 2026
  • 2028 onwards: Potential NHS availability, subject to NICE technology appraisal – a process that can add 12-24 months after MHRA approval

These timelines are estimates. The dysesthesia signal from TRIUMPH-4 will require explanation before regulators are satisfied. Anyone presenting retatrutide as imminent on UK prescriptions is not reading the timeline accurately.

Separate from the prescription medicine pathway, research-grade retatrutide is available in the UK as a research chemical for in vitro laboratory use – the same regulatory framework that applies to BPC-157, TB-500, and other investigational peptides.

Rachel runs a metabolic biology research unit in Bristol. She had been using semaglutide analogues as control compounds in in vitro receptor binding studies. When the TRIUMPH-4 data came out, she wanted to add retatrutide to her receptor characterisation work – specifically to study the glucagon receptor agonism component in isolated adipocyte models. She sourced research-grade retatrutide with independent COA documentation from Pure Grade Labs. The compound she needed for in vitro work was available. The prescription medicine version wasn’t. These are two completely separate tracks.

Frequently Asked Questions

What makes retatrutide different from semaglutide?

Semaglutide (Ozempic, Wegovy) activates only the GLP-1 receptor. Retatrutide activates three receptors simultaneously: GLP-1, GIP, and glucagon. The GIP agonism adds insulin sensitivity and lipid metabolism effects. The glucagon receptor agonism adds energy expenditure (thermogenesis), hepatic fat oxidation, and lipolysis – mechanisms not present in semaglutide. In Phase 3 trials, retatrutide has produced approximately 8-10 percentage points greater mean weight loss than semaglutide.

Is retatrutide available in the UK?

No. As of April 2026, retatrutide has not received MHRA Marketing Authorisation and cannot be prescribed or dispensed through NHS or licensed private prescribers in the UK. The earliest realistic timeline for prescription availability is 2028, assuming Phase 3 data is positive and regulatory submissions proceed on the expected schedule. Research-grade retatrutide is available separately for in vitro laboratory research use.

What were the Phase 3 TRIUMPH-4 results?

TRIUMPH-4 reported in December 2025 in 445 adults with obesity or overweight and knee osteoarthritis. The 12 mg dose produced 28.7% mean body weight reduction (approximately 32.3 kg / 71.2 lbs) at 68 weeks – the largest result in any obesity pharmacotherapy trial to date. A new safety signal was also observed: dysesthesia (abnormal skin sensation) in 8.8% at 9 mg and 20.9% at 12 mg, compared to 0.7% on placebo. Seven additional Phase 3 trials are expected to report in 2026.

How does retatrutide compare to tirzepatide?

Tirzepatide (Mounjaro) is a dual GLP-1/GIP agonist. Retatrutide adds glucagon receptor agonism. In separate Phase 2 and Phase 3 trials (not a head-to-head study), retatrutide has produced approximately 6 percentage points greater weight loss than tirzepatide’s best results. Retatrutide has also shown substantially greater liver fat reduction (up to 82%) compared to tirzepatide. Whether this superiority holds in a direct head-to-head comparison has not been established.

What are the known side effects of retatrutide?

Phase 2 trials showed a side effect profile consistent with other GLP-1-containing therapies: nausea, vomiting, diarrhoea, and constipation, primarily during dose escalation, mostly mild-to-moderate, and diminishing over time. TRIUMPH-4 identified a new signal not seen with semaglutide or tirzepatide: dysesthesia (abnormal skin tingling or pain) in 8.8% at 9 mg and 20.9% at 12 mg. The mechanism and clinical significance of this signal are under investigation. Long-term safety data from the full Phase 3 programme is still being gathered.

Research-Grade GLP-1 Compounds. Verified Every Batch.

Retatrutide and the full range of metabolic research peptides. HPLC purity verified. Mass spectrometry identity confirmed. UK research chemical supplier.

Get Pure Grade Peptides →

Summary

Retatrutide is the most advanced triple hormone receptor agonist in clinical development for obesity and metabolic disease. Its mechanism – simultaneous GLP-1, GIP, and glucagon receptor activation – is pharmacologically distinct from every approved obesity medicine. The glucagon component is the critical differentiator: it drives energy expenditure and hepatic fat oxidation that GLP-1 and GIP pathways cannot replicate.

Phase 2 established 24.2% weight loss at 48 weeks. Phase 3 TRIUMPH-4 extended this to 28.7% at 68 weeks – the largest weight loss result ever recorded in an obesity pharmacotherapy trial. Liver fat reduction of up to 82% in Phase 2a positions retatrutide as a potentially transformative treatment for MASH, where no approved option currently exists. The new dysesthesia signal in TRIUMPH-4 requires full characterisation before regulatory submission.

For the UK: prescription retatrutide is years away – realistic availability is 2028 at earliest, contingent on the remaining Phase 3 data, regulatory submissions, and NICE appraisal. Research-grade retatrutide is available now for in vitro laboratory use under the same research chemical framework that applies to other investigational peptides.

References

  1. Jastreboff AM et al. (2023). Triple-Hormone-Receptor Agonist Retatrutide for Obesity – A Phase 2 Trial. New England Journal of Medicine, 389(6):514-526. DOI: 10.1056/NEJMoa2301972
  2. Rosenstock J et al. (2023). Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, phase 2 trial. The Lancet, 402(10401):529-544
  3. Alkhouri N et al. (2024). Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease. Nature Medicine. DOI: 10.1038/s41591-024-03018-2
  4. Eli Lilly and Company. (December 2025). Lilly’s triple agonist, retatrutide, delivered weight loss of up to an average of 71.2 lbs in first successful Phase 3 trial. Press release. investor.lilly.com
  5. Coskun T et al. (2022). LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss. Cell Metabolism, 34:1234-1247
Disclaimer: This article is for research and informational purposes only. Retatrutide has not received MHRA, FDA, or EMA marketing authorisation and cannot be prescribed or dispensed in the UK. Research-grade retatrutide from Pure Grade Labs is sold for in vitro laboratory research purposes only and is not intended for human consumption. This content does not constitute medical advice. For weight management options currently available in the UK, speak with your GP.